A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 31 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Nov 2021 Results assessing Genetic Risk Score to Predict Peripheral Artery Disease from ENGAGE AF-TIMI 48, SOLID-TIMI 52, SAVOR-TIMI 53, PEGASUS-TIMI 54, and FOURIER trials presented at the American Heart Association Scientific Sessions 2021
16 Nov 2016 Results assessing the risk of adverse limb events in patients with peripheral artery disease post-acute coronary syndrome (n=13009), presented at the 89th Annual Scientific Sessions of the American Heart Association
13 May 2014 Top-line results reported in a GlaxoSmithKline media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com